We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Zoetis (ZTS) Stock Outpacing Its Medical Peers This Year?
Read MoreHide Full Article
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has Zoetis (ZTS - Free Report) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out.
Zoetis is a member of the Medical sector. This group includes 840 individual stocks and currently holds a Zacks Sector Rank of #2. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. ZTS is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for ZTS's full-year earnings has moved 1.24% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Based on the most recent data, ZTS has returned 17.98% so far this year. Meanwhile, the Medical sector has returned an average of -3.45% on a year-to-date basis. This shows that Zoetis is outperforming its peers so far this year.
Looking more specifically, ZTS belongs to the Medical - Drugs industry, which includes 180 individual stocks and currently sits at #93 in the Zacks Industry Rank. On average, stocks in this group have lost 14.48% this year, meaning that ZTS is performing better in terms of year-to-date returns.
ZTS will likely be looking to continue its solid performance, so investors interested in Medical stocks should continue to pay close attention to the company.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is Zoetis (ZTS) Stock Outpacing Its Medical Peers This Year?
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has Zoetis (ZTS - Free Report) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out.
Zoetis is a member of the Medical sector. This group includes 840 individual stocks and currently holds a Zacks Sector Rank of #2. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. ZTS is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for ZTS's full-year earnings has moved 1.24% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Based on the most recent data, ZTS has returned 17.98% so far this year. Meanwhile, the Medical sector has returned an average of -3.45% on a year-to-date basis. This shows that Zoetis is outperforming its peers so far this year.
Looking more specifically, ZTS belongs to the Medical - Drugs industry, which includes 180 individual stocks and currently sits at #93 in the Zacks Industry Rank. On average, stocks in this group have lost 14.48% this year, meaning that ZTS is performing better in terms of year-to-date returns.
ZTS will likely be looking to continue its solid performance, so investors interested in Medical stocks should continue to pay close attention to the company.